MaxCyte Beats Estimates, Announces Buyback as Strategic Growth Outweighs Core Revenue Dip

ROCKVILLE, MD – May 12, 2026 – MaxCyte, Inc. (NASDAQ: MXCT) today presented a complex but ultimately confident picture of its business, announcing first-quarter financial results that beat analyst expectations and unveiling a $10 million share repurchase program. The cell-engineering firm reported a significant improvement in profitability and strong growth in its high-value strategic partnerships, even as it navigated a notable downturn in its core business revenue.

The company posted total revenue of $9.7 million for the quarter ended March 31, 2026, a figure that, while down 7% from the prior year, comfortably surpassed Wall Street's consensus estimate of $7.3 million. More impressively, MaxCyte dramatically narrowed its net loss to $4.8 million, or $0.04 per share, from a loss of $10.3 million, or $0.10 per share, in the same period of 2025. This performance handily beat the forecasted loss of $0.08 per share. Amidst the mixed revenue signals, the company reiterated its full-year 2026 guidance and signaled strong belief in its long-term value with the new buyback authorization.

A Tale of Two Revenue Streams

A deeper look into MaxCyte's Q1 performance reveals a story of two distinct business segments moving in opposite directions. The company's core revenue—derived from the sale of its ExPERT electroporation instruments, disposable processing assemblies (PAs), and related services—fell 25% year-over-year to $6.2 million.

This decline was most pronounced in the PAs and consumables category, which dropped 41% from $3.9 million to $2.3 million. The company attributed the softness to a combination of factors, including inventory management by its largest customers and the lingering effects of discontinued partner programs. This reflects a broader trend of cautious spending and inventory optimization across the biotech sector.

In stark contrast, revenue from MaxCyte’s Strategic Platform License (SPL) program surged 50% to $3.4 million. This segment represents the long-term value proposition of the company, where partners pay significant fees and future royalties for access to MaxCyte’s technology for their clinical and commercial therapeutic programs. The Q1 growth was fueled by a $3 million milestone payment from a clinical partner that began dosing patients in a registrational study—a critical late-stage step before seeking regulatory approval. This milestone-driven revenue, while inherently lumpy, underscores the tangible progress of MaxCyte's technology in the hands of leading cell therapy developers.

“We are pleased with our performance in the first quarter, and remain confident in our full year guidance,” said Maher Masoud, President and CEO of MaxCyte, in the company's press release. He noted that the SPL portfolio continues to advance, with expectations that additional customers will initiate their own registrational trials this year.

Disciplined Operations and Shareholder Confidence

The most significant positive in the report was the dramatic improvement in the company's bottom line. The halving of the net loss was not an accident but the result of deliberate cost-cutting and restructuring actions undertaken in 2025. Total operating expenses were slashed by 33%, falling to $14.3 million from $21.2 million in the prior-year quarter. This newfound operational efficiency allowed the company to maintain a robust gross margin of 84%.

This display of financial discipline provides the context for the Board of Directors' decision to authorize a $10 million share repurchase program. Such a move is widely interpreted by investors as a strong signal from management that they believe the company's stock is undervalued and that they are confident in its future prospects. With a healthy balance sheet showing $147.7 million in cash, cash equivalents, and investments, MaxCyte is positioning itself to both reinvest in growth and return capital to shareholders.

“Reflecting continued confidence in our strategy and the long-term value of our business, the Board today authorized a $10 million share repurchase,” Masoud stated. “This authorization provides us with flexibility in capital allocation while we continue to invest in key growth initiatives... We believe this balanced approach enables us to both reinvest in the business and return capital to shareholders.”

The Engine of Growth: A Maturing SPL Portfolio

While core instrument sales may fluctuate with short-term market dynamics, the long-term health of MaxCyte is intrinsically linked to the success of its SPL partners. The company's technology is a foundational component in some of the most advanced cell and gene therapy programs in the world. As of the end of the quarter, MaxCyte had 29 active SPL agreements, a portfolio that includes 12 programs in clinical trials and one therapy, CASGEVY, already on the market.

The recent milestone from a partner initiating a registrational study is a powerful proof point. Each program that advances to this late stage not only triggers potential milestone payments but also moves one step closer to generating a steady stream of commercial royalties for MaxCyte. The company has expressed confidence that this is just the beginning, with management anticipating that four additional SPL programs could enter pivotal registrational trials within the next 18 months. This growing pipeline of late-stage assets represents a significant, de-risked opportunity for future revenue and solidifies MaxCyte's role as a critical enabler in the commercialization of next-generation medicines.

Navigating a Complex Biotech Landscape

MaxCyte’s Q1 results serve as a microcosm of the broader cell and gene therapy industry—a field marked by immense long-term promise but subject to short-term volatility and funding headwinds. The "softer demand" seen in MaxCyte's core business is reflective of a more cautious capital environment for many early-stage biotech companies, which may be delaying equipment purchases or managing consumable inventory more tightly.

However, the simultaneous growth in the SPL segment shows that investment in late-stage, high-potential clinical programs remains robust. Companies with promising therapies are continuing to push them toward the finish line, and they require best-in-class enabling technologies like MaxCyte's Flow Electroporation® platform to do so. This dynamic positions MaxCyte advantageously. Its strong balance sheet and leaner operating structure provide resilience against market headwinds, while its maturing portfolio of high-value partnerships offers a clear, long-term path to significant growth.

Looking ahead, the company reiterated its full-year 2026 revenue guidance of $30 million to $32 million. This forecast assumes a recovery and strengthening of its core business in the second half of the year, alongside approximately $5 million in revenue from its SPL program. With plans to end the year with at least $136 million in cash, excluding the new buyback, MaxCyte appears well-capitalized to execute its strategy and cement its leadership position in the cell-engineering revolution.